Gastrointestinal Mucormycosis of the Jejunum in an Immunocompetent Patient

A Case Report

Mengqing Sun, MD, Xianming Hou, MPH, Xiaoting Wang, MD, Ge Chen, MD, Yupei Zhao, MD

Abstract

Rationale: Gastrointestinal Mucormycosis (GIM) is a kind of opportunistic fungal infection with poor prognosis. It usually occurs in patients with immune deficiency. We reported a case of immunocompetent male patient.

Patient concerns: This patient was presented as abdominal distension and gastrointestinal bleeding.

Diagnoses: A variety of hemostatic methods was ineffective to stop the bleeding. The patient finally received laparotomy, and the jejunum lesions were found.

Interventions: Pathological examination confirmed it to be gastrointestinal mucormycosis in jejunum.

Outcomes: However, after systemic anti-fungi therapy, the patient died of septic shock.

Lessons: The diagnosis mainly relies on pathological examination. Early diagnosis and early application of systemic amphotericin B or liposome were fundamental for improving the prognosis.

Abbreviations: Amp B = amphotericin B, BP = blood pressure, CTA = computer tomography angiography, DBil = direct bilirubin, GIM = gastrointestinal bleeding, GIM = gastrointestinal mucormycosis, HGB = hemoglobin, HR = heart rate, ICU = intensive care unit, K = potassium, NEUT = neutrophil, PET-CT = positron emission tomography-computer tomography, POD = postoperation day, RR = respiratory rate, T = temperature, TBil = total bilirubin, WBC = white blood cell.

Keywords: gastrointestinal bleeding, gastrointestinal tract, mucormycosis

1. Background

Mucormycosis is an opportunistic infection caused by condition-al fungal pathogens. It is characterized by vascular invasion by the hyphae, leading to thrombosis and necrosis. Mucormycosis can occur in the head and neck, lung, skin, gastrointestinal tract, and central nervous system, causing the corresponding symptoms. Most patients with gastrointestinal mucormycosis (GIM) are immunocompromised, and an immunocompetent host with GIM is rare. Here, we report a case of mucormycosis that affected the gastrointestinal tract. The patient had no evidence of immunosuppression. A literature review is also presented. Informed consent was obtained in this study. The Ethical Committee of Peking Union Medical College Hospital approved the present study, and the patient approved with a written consent before the surgery.

2. Case report

A 66-year-old male patient presented with a past medical history of rheumatic heart disease and mitral stenosis for more than 10 years and has been taking oral warfarin anticoagulation. Sixteen days before admission, he had abdominal distension, nausea, and fever, with a T_{max} of 39°C. Thirteen days earlier, the abdominal distention had become worse. An enema was performed, and the patient was admitted to the intensive care unit (ICU) ward, and cefoperazone/sulbactam was prescribed. The patient had symptoms of abdominal distension and gastrointestinal bleeding. On the morning of admission, the patient had dyspnea, with a respiratory rate (RR) of 30/min, and he came to the emergency room of our hospital.

2.1. Hospital course

The patient’s vital signs were as follows: T: 36.8°C, heart rate (HR): 156 bpm, RR: 28/min, blood pressure (BP): 91/63 mm Hg, and SpO2: 99%. The breathing sound of the bilateral lower pulmonary field was low, and scattered wet rales could be heard. The laboratory examination results were as follows: hemoglobin (HGB) 84 g/L, white blood cell (WBC) count 8.51×10^9/L, neutrophil% (NEUT%) 83.2%, and potassium (K) 3.1 mmol/L; other results, including the complete blood count, liver function, renal function, and electrolytes, were normal. The patient was admitted to the intensive care unit (ICU) ward, and cefoperazone/sulbactam was prescribed. The patient had symptoms of
gastrointestinal bleeding (GIB) during the night with hematochezia and positive occult blood in both his stool and gastric juice. The HGB was reduced to 65g/L. Three days after admission, the patient received an examination by gastroscopy, and a jejunum nutrition tube was inserted. The gastroscopic results showed multiple lesions in the horizontal part of the duodenum, and a biopsy was performed (Fig. 1). The pathological examination suggested inflammatory exudates, and acute and chronic inflammation of the small intestinal mucosa. Fungal hyphae were seen in the inflammatory exudates, which were considered mucor (Fig. 2).

Due to the continuous gastrointestinal bleeding, an interventional therapy of artery embolization was performed on day 5 to stop the bleeding. The gastroduodenal artery proximal to the right gastroepiploic artery was embolized. The patient still had hematochezia after the intervention. A positron emission tomography-computer tomography (PET-CT) and an abdominal computer tomography angiography (CTA) examination were performed, but no obvious bleeding site was found. Because of the ineffectiveness of the variety of hemostatic methods, laparotomy and intraoperative gastroscopy exploration were performed on day 6. During the operation, we observed adhesions of the jejunal wall 15 cm from the Treitz ligament with the surrounding small mesentery. There was a hard, palpable mass 5 cm in size. After decomposition of the adhesion, the site of chronic perforation could be observed in the jejunal wall. The site of the GIB was the proximal jejunum. The perforation site and the distended proximal jejunum were resected. A drainage tube was placed near the anastomosis, and a jejunum fistula tube was placed 50 cm from the anastomosis. The abdominal drainage fluid was collected for a pathogen culture.

The results of the culture returned on postoperation day (POD) 4 suggested Candida albicans, Klebsiella pneumoniae, and Acinetobacter baumannii. Caspofungin was prescribed for antifungal therapy. Cefoperazone/sulbactam, minocycline, and vancomycin were used for empirical antibiotic therapy. The patient’s temperature returned to normal. Minocycline, vancomycin, and caspofungin were terminated on POD 11. The cefoperazone/sulbactam was withdrawn, and the abdominal drainage tube was removed on POD 14.

Heparin anticoagulant therapy was initiated on POD 17 for the rheumatic heart disease. Melena reappeared. The patient’s HGB decreased to 86 g/L. Heparin was stopped, and the patient received a blood transfusion. The hematochezia did not improve. The plasma fungal D-glucan (G test) was 112.80 pg/mL. The pathologists re-examined the ulcer lesion of the surgical specimen and found degenerative fungal hyphae. The morphology and specific staining suggested it was a mucor infection (Fig. 3). Oral mycostatin and intravenous amphotericin B (Amp B) were initiated on POD 26. Amp B was initiated at a dose of 5 mg daily, which was gradually increased to 20 mg daily. The patient had a fever, abdominal distension, and an increase in bilirubin, with a total bilirubin (TBil) of 36.2 mol/L and a direct bilirubin (DBil) of 26.7 mol/L. We considered these results adverse effects of Amp B, and gradually reduced the dose to 15 mg/d. After 20 days of medication, we withdrew the Amp B and used the single drug mycostatin. During the drug treatment, the patient’s gastrointestinal bleeding gradually stopped, and the temperature remained normal. Six weeks after the operation, the patient was transferred from the ICU to the general surgery ward to continue the

Figure 1. Gastroscopic examination. 1 = Multiple lesions were found in the horizontal portion of the duodenum, 2 = a small amount of fresh bleeding.

Figure 2. The pathological examination of the gastroscopic biopsy specimen. Fungal hyphae can be observed in the inflammatory exudates.
treatment of oral mycostatin until drug withdrawal. The total course of antifungal treatment with Amp B and mycostatin was 4 weeks. Nine weeks after the operation, the jejunal fistula tube was removed. The patient’s body temperature was normal, and there was no evidence of gastrointestinal bleeding. The patient was discharged.

Four days after discharge, the patient again developed nausea, vomiting, and left abdominal pain with a body temperature up to 38.9°C. The following day, the patient developed abdominal distension. After an enema, about 1000mL of loose stool was discharged. Subsequently, the patient had diarrhea approximately 8 times a day, with a total of approximately 1000mL. The patient complained that he was thirsty. One week after discharge, the patient had delirium, weak breathing, confusion, and oliguria. He was re-admitted to the hospital, and septic shock was considered. Anti-infection therapy and active drug treatment were ineffectual, and the patient was declared dead.

3. Discussion
Mucormycosis can occur in many parts of the human body, such as the head and neck, lung, skin, gastrointestinal tract, central nervous system, and primarily in the nasal cavity. GIM accounts for only 7% of all cases, but the mortality rate can be as high as 85%. Mucormycosis in the gastrointestinal tract is most commonly observed in the stomach, followed by the small intestine and colon. The clinical presentation of the disease can be manifested as ischemic bowel disease or gastrointestinal bleeding. The diagnosis depends on the pathological examination.

The prognosis of GIM is poor, and the disease has a high mortality. Most patients have factors of immune deficiency, such as organ transplantation, hematological malignancies, and glucocorticoid steroid therapy. The pediatric literature has reported a number of cases of neonatal necrotizing enterocolitis caused by mucormycosis. GIM in an immunocompetent host is rare.

We searched the cases of GIM in immunocompetent adults that have been reported in the English literature since 2000. A total of 9 cases were retrieved. These cases are summarized in Table 1.

In the 9 cases, we found the following: 4 cases of GIM occurred in the stomach; 5 cases of GIM occurred in the colon (including 1 case occurring both in the stomach and the colon); and 1 case of GIM occurred in the abdominal cavity after a trauma. Here, we report an immunocompetent adult case of GIM occurring in the jejunum, which has not been reported in the literature. However, GIM of the jejunum has been reported in immunocompromised patients. Agha et al. summarized 87 cases of GIM in immunodeficient patients, and only 1 case occurred in the jejunum. The diagnosis of this disease mainly relies on the pathological examination. All 9 cases shown in Table 1 were diagnosed by surgery, endoscopic biopsy, or autopsy. The diagnosis of the patient we reported here was also diagnosed by the pathology of the gastrointestinal and surgical biopsy.

Almost all the cases reported in the literature had different underlying symptoms, such as fever, respiratory symptoms, or trauma, and then gradually developed gastrointestinal bleeding.

### Table 1
Summary of the cases of gastrointestinal mucormycosis in immunocompetent adults that are reported in the English language literature since 2000.

| No. | Sex | Age | Location                  | Clinical presentation                      | Diagnosis                      | Treatment and result                                                                 | Reference |
|-----|-----|-----|---------------------------|-------------------------------------------|-------------------------------|-------------------------------------------------------------------------------------|-----------|
| 1   | F   | 58  | Sigmoid colon             | Hematochezia                              | Laparoscopic exploration      | Hartmann procedure; fluconazole; Amp B; death                                        | [26]      |
| 2   | M   | 28  | Stomach                   | Hematochezia, hematemesis, abdominal pain | Gastroscopic biopsy           | Amp B; death                                                                       | [27]      |
| 3   | M   | 58  | Abdominal cavity          | Posttraumatic peritoneal irritation sign   | Laparotomy and liver biopsy   | Amp B, miconafungin, posaconazole; cured with no recurrence                         | [9]       |
| 4   | F   | 70  | Ascending colon           | GIB, septic Shock                         | Colonoscopy, autopsy          | Death                                                                               | [28]      |
| 5   | M   | 58  | Stomach                   | Hematemesis, shock, jaundice              | Gastroscopy, laparotomy, and biopsy | Amp B, miconafungin, posaconazole; cured with no recurrence                         | [29]      |
| 6   | M   | 69  | Colon                     | Fever, shock                              | Subtotal colectomy, pathologi- | Amp B; death                                                                       | [3]       |
| 7   | M   | 48  | Stomach                   | Posttraumatic hematochezia, abdominal pain| Laparotomy and endoscopic biopsy| Amp B; death                                                                       | [10]      |
| 8   | F   | 58  | Colon                     | GIB                                        | Laparotomy and biopsy         | Right hemicolectomy; intestinal resection; Amp B; miconafungin; death               | [11]      |

Amp B = amphotericin B, GIB = gastrointestinal bleeding.
such as hematochezia or hematemesis. Once gastrointestinal bleeding appeared, the patient's condition tended to deteriorate rapidly with the occurrence of septic shock or multiple organ failure. Of the 9 patients we summarized, only 2 patients were cured without recurrence.

Most of the mucormycosis cases are caused by environmental exposure. The most common site of infection is the nasal cavity. GIM in an immunocompetent host is very rare. It is likely that an underlying disease, such as respiratory infections or viral infections, causes a temporary decline in the immune system, and the fungi in the nasal cavity, parapharynx, or other common infection site invade the blood vessel walls and disseminate to the gastrointestinal tract, causing ulceration and perforation. In this case, the patient developed a fever 16 days before admission, which may have been the cause of the temporary decline in immunity. The rapid increase in GIB may be related to the long-term anticoagulation because of rheumatic heart disease and mitral stenosis.

The treatment of GIM includes surgical resection of the lesions, systemic application of antifungal drugs, and support therapy. For patients with an immunodeficiency, correction of the underlying disease is also very important.

3.1. Surgical resection of the lesion

The surgical treatment of GIM usually occurs in a passive time, such as during emergency laparotomy, debridement, and drainage. The symptoms arising before the surgery are usually nonspecific emergent presentations, such as bleeding and perforation. In addition, as reported in the present case, the diagnosis of the disease also depends on surgical resection or biopsy of the specimen, followed by a pathological examination rather than microbiological culture.[11] Therefore, it is difficult to diagnose the disease before surgery.

Regarding the purpose of the surgery, because the disease can cause thrombosis and necrosis of the gastrointestinal tract and the surrounding tissue, the effectiveness of only antifungal therapy without surgery will be poor. There are 2 cases of successful treatment shown in Table 1.[9,10] A study of the 2 cases suggested that in operating on such a special infectious disease, complete elimination of the necrotic tissue and sufficient drainage should be the purpose of the operation. In addition, it may be helpful for the patient.[9–11]

3.2. Systemic therapy

The systemic application of antifungal drugs is another major basis for the treatment of mucormycosis. The early initiation of antifungal therapy improves the outcome of mucormycosis infection.[12] Unfortunately, the experience of using antifungal drugs reported in the literature is mostly for immunocompromised patients with no gastrointestinal involvement. However, based on experiences of antifungal therapy in other lesions, we can generally conclude the following.

Amphotericin B is currently recommended as a first-line drug. Amp B liposome is also noteworthy. Compared with deoxycholate and the lipid complex forms of amp B, amp B liposome has a relatively low renal toxicity, which is advantageous for long-term use and larger doses of medication. Moreover, some reports have noted that the application of amp B liposome is more effective for patients with mucormycosis.[13,14]

Flucytosine, voriconazole, and itraconazole do not have reliable activity against mucormycosis.[15] Posaconazole is not used as a first-line drug because it is unsatisfactory in plasma concentrations,[15,16] ineffective in animal models,[17] and has failed in prophylactic use.[18] However, it is noteworthy that posaconazole has demonstrated efficacy in the patients with polyenes intolerance, such as neutropenia.[19] Therefore, it was a choice between combination therapy and remedial treatment.

Echinocandin drugs, such as caspofungin, are first-line antifungal drugs. They are mainly used in invasive Aspergillus infections in which other antifungal agents are ineffective or poorly tolerated. Although the echinocandins (eg, caspofungin) have no in vitro activity against the agents of mucormycosis, [20] Rhizopus oryzae, the most common cause of mucormycosis, expresses the target enzyme for echinocandins, suggesting that these agents may have clinical utility.[21] For some types of mucor, several laboratory studies suggest that echinocandins combined with amp B can produce a better effect.[22] However, this conclusion still lacks the support of large-scale clinical trials.

3.3. Other auxiliary therapy

3.3.1. Iron-chelating agents

Iron is required by virtually all microbial pathogens for growth and virulence.[23] Unlike deferoxamine combined with iron that can be used as an iron carrier by pathogens and enhance the pathogenicity, after combining with iron, deferasirox can reduce the iron content to reduce the fungal load and, thus, improve survival. Therefore, deferasirox has a potential therapeutic value in treating mucormycosis. However, in some clinical studies, the combination of deferasirox and amp B did not produce a better prognosis.[24] Whether deferasirox can improve the prognosis or be used as an alternative treatment option still requires confirmation with more reliable clinical studies. In contrast to patients with diabetes or ketoacidosis, our immunocompetent patient had normal iron metabolism, and the effectiveness of deferasirox remained questionable.

3.3.2. Proinflammatory cytokines, such as interferon-γ, and granulocyte-macrophage colony-stimulating factor (GM-CSF)

These drugs are used to correct the patients' immune condition, thereby improving their prognosis. The effectiveness of such treatments is still controversial. For immunocompetent patients with GIM, no theoretical basis exists for this application. From the literature, we find that in the 9 cases reported, only 2 patients were successfully cured with no relapse, and both cases involved posttraumatic (gunshot wounds, car accident) onsets. One patient underwent multiple debridement and drainage, and the other had a splenectomy, subtotal colectomy, terminal ileum resection, and multiple intraperitoneal irrigations.[9,10] The systemic antifungi therapy in both of these patients included amp B, micafungin, and posaconazole. The basic drug regimen is amp B, combined with micafungin, as soon as possible after the diagnosis. Depending on the patient's general condition, such as leukopenia, posaconazole could be used. More interestingly, in a report of invasive mold infections after combat-related injuries, of a total of 37 patients, 16 were diagnosed as with mucormycosis, of which only 3 patients died, although the majority of patients had limb lesions.[25] It appears that mucormycosis caused by trauma has a relatively good prognosis.

4. Conclusions

Gastrointestinal mucormycosis in immunocompetent patients is a rare disease, especially in the jejunum. The disease has a high mortality. The diagnosis of this disease mainly relies on a
pathological examination, either by surgery, endoscopic biopsy, or autopsy. For immunocompetent patients with GIM, early diagnosis and early application of systemic amphotericin B liposome were fundamental for improving the prognosis. Aggressive surgical treatment is also important. Patients with a traumatic onset appear to have a relatively good prognosis.

References
[1] Antony SJ, Parikh MS, Ramirez R, et al. Gastrointestinal mucormycosis resulting in a catastrophic outcome in an immunocompetent patient. Infect Dis Rep 2015;7:603.
[2] Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54(suppl 1):S23–34.
[3] Choi HL, Shin YM, Lee KM, et al. Bowel infarction due to intestinal mucormycosis in an immunocompetent patient. J Korean Surg Soc 2012;83:323–9.
[4] Spellberg B. Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol 2012;8:140–2.
[5] Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol 2013;8:1163–75.
[6] Vallabhaneni S, Walker TA, Lockhart SR, et al. Centers for Disease Control and PreventionNotes from the field: gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement: Connecticut, 2014. MMWR Morb Mortal Wkly Rep 2015;64:155–6.
[7] Martiniello M, Nelson A, Bignold L, et al. We are what we eat!\[5\] Dietary supplement: Connecticut, 2014. MMWR Morb Mortal Wkly Rep 2015;64:155–6.

[8] Agha FP, Lee HH, Boland CR, et al. Mucormycosis of the colon: early diagnosis and successful management. AJR Am J Roentgenol 1985;145: 739–41.
[9] Van Sickels N, Hoffman J, Stuke L, et al. Survival of a patient with mucormycosis in an immunocompetent person. J Postgrad Med 2008;44:211–3.
[10] Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphoteratin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503–9.
[11] Gleissner B, Schilling A, Anagnostopolous I, et al. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymph 2004;45:1331–60.
[12] Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010;65:296–302.

[13] Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581–2.
[14] Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:638–46.
[15] Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009;53:772–5.
[16] Lekakis IJ, Lawson A, Prante J, et al. Fatal rhizopus pneumonia in an immunocompetent patient. J Postgrad Med 2008;44:211–3.
[17] Ibrahim AS, Bowman JC, Avanesian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005;49:721–7.
[18] Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364–71.
[19] Bullen JJ, Rogers HJ, Spalding PB, et al. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol 2006;55(Pt 3):251–8.
[20] Spellberg B, Ibrahim AS, Chun-Hong PV, et al. The Deferasirox-Aspergillosis Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67:715–22.
[21] Warkentien T, Rodriguez C, Lloyd B, et al. Invasive mold infections following combat-related injuries. Clin Infect Dis 2012;55:1441–9.
[22] Sakorafas GH, Tsalokides G, Grigoriades K, et al. Colonic mucormycosis: an exceptionally rare cause of massive lower gastrointestinal bleeding. Digestive and liver disease: of interest to the European Society for Clinical Microbiology and Infectious Diseases. J Med Microbiol 2006;55:1351–3.